Transcriptome analysis of primary adult B‐cell lineage acute lymphoblastic leukemia identifies pathogenic variants and gene fusions, and predicts subtypes for in depth molecular diagnosis

Author:

Podgorica Mirjam12ORCID,Drivet Elsa12ORCID,Viken Jonas Krag123,Richman Alyssa4ORCID,Vestbøstad Johanne12ORCID,Szodoray Peter5ORCID,Kvam Ann Kristin6ORCID,Wik Hilde Skuterud6ORCID,Tjønnfjord Geir E.26ORCID,Munthe Ludvig A.12ORCID,Frietze Seth4ORCID,Schjerven Hilde1237ORCID

Affiliation:

1. Department of Immunology Oslo University Hospital Oslo Norway

2. KG Jebsen Center for B‐cell Malignancies, Institute of Clinical Medicine, Department of Immunology University of Oslo Oslo Norway

3. Department of Laboratory Medicine University of California San Francisco San Francisco California USA

4. Department of Biomedical and Health Sciences University of Vermont Burlington Vermont USA

5. B Cell Receptor Signaling Group (BCRSG), Department of Immunology Oslo University Hospital Oslo Norway

6. Department of Haematology Oslo University Hospital Oslo Norway

7. Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco California USA

Abstract

AbstractBackgroundB‐cell acute lymphoblastic leukemia (B‐ALL) is classified into subgroups based on known driver oncogenes and molecular lesions, including translocations and recurrent mutations. However, the current diagnostic tests do not identify subtypes or oncogenic lesions for all B‐ALL samples, creating a heterogeneous B‐ALL group of unknown subtypes.MethodsWe sorted primary adult B‐ALL cells and performed transcriptome analysis by bulk RNA sequencing (RNA‐seq).ResultsTranscriptomic analysis of an adult B‐ALL cohort allowed the classification of four patient samples with subtypes that were not previously revealed by standard gene panels. The leukemia of two patients were of the DUX4 subtype and two were CRLF2+ Ph‐like B‐ALL. Furthermore, single nucleotide variant analysis detected the oncogenic NRAS‐G12D, KRAS‐G12D, and KRAS‐G13D mutations in three of the patient samples, presenting targetable mutations. Additional oncogenic variants and gene fusions were uncovered, as well as multiple variants in the PDE4DIP gene across five of the patient samples.ConclusionWe demonstrate that RNA‐seq is an effective tool for precision medicine in B‐ALL by providing comprehensive molecular profiling of leukemia cells, identifying subtype and oncogenic lesions, and stratifying patients for appropriate therapy.

Funder

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco

Helse Sør-Øst RHF

National Institutes of Health

Livsvitenskap, Universitetet i Oslo

Publisher

Wiley

Subject

Hematology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3